Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia A

NCT00306670 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT00306670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00306670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia A
Lead sponsor
Georgetown University
Phase
Phase 2/3
Overall status
Terminated
Start date
April 30, 2006
Completion date
August 31, 2011
Enrollment
2 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a